Pharmacology Consult

Risk-based approach must guide VTE prophylaxis for ambulatory patients with cancer

HemOnc Today, February 25, 2019
Jai N. Patel, PharmD, BCOP
Individuals with cancer are more than four times as likely as those in the general population to develop venous thromboembolism. Chemotherapy receipt…
Editorial

Prostate cancer trials: Waiting for Godot

HemOnc Today, February 25, 2019
Derek Raghavan, MD, PhD
In an era in which we are ever more hurrying to find truth, and the FDA is exploring a range of surrogate endpoints to support early introduction of…
Point/Counter

Will targeted therapies become the mainstay of AML treatment?

HemOnc Today, February 25, 2019
POINT After a long drought, the past 2 years have seen a flurry of drug approvals in AML, including three highly specific agents that target discrete…
Cover Story

Targeted treatments for acute myeloid leukemia yield modest improvements, great hope

HemOnc Today, February 25, 2019
Acute myeloid leukemia historically has been one of the more deadly and difficult-to-treat cancers, with a 5-year survival rate below 30%. Moreover…
Feature

Rose geranium oil may improve nasal symptoms associated with cancer-directed therapy

February 12, 2019
Rose geranium oil appeared to ease the symptoms of nasal vestibulitis — a common condition associated with cancer treatment — among a…
Feature

Protein-targeting vaccine extends survival in glioblastoma

February 8, 2019
A vaccine that targets the protein survivin appeared safe and extended survival among patients with newly diagnosed glioblastoma, according to…
Molecular Oncology

Personalized context of the cancer cell

HemOnc Today, February 10, 2019
Sofia D. Merajver, MD, PhD
For decades, prognostic markers and therapeutics have been focused largely on the cancer cell’s growth patterns in tissue culture or in animal…
Feature

Researchers tap genomic technology to develop personalized treatments for pediatric glioma

February 3, 2019
Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade…
Meeting News

DA-EPOCH shows promise in newly diagnosed acute lymphoblastic leukemia

January 24, 2019
SAN DIEGO — Researchers at the ASH Annual Meeting and Exposition reported that dose-adjusted etoposide, prednisone, vincristine…
Feature

Solutions needed to lower 'unsustainable cost' of care for hematologic malignancies

January 23, 2019
Treatment costs for hematologic malignancies exceed those of other cancer types, and they place lasting burdens on patients and the health care…